Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Authors
Peter Nash (ORCID: https://orcid.org/0000-0002-2571-788X)
Jason Eells
V. Taieb (ORCID: https://orcid.org/0000-0003-0655-8630)
Iain B. McInnes (ORCID: https://orcid.org/0000-0002-6462-4280)
Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Peter Nash, Jason Eells, V. Taieb, Iain B. McInnes et al.
Citations
2 citations
Journal
Rheumatology and Therapy
Topics
Spondyloarthritis Studies and Treatments
Field-Weighted Citation Impact (FWCI)
0.94
article
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Peter Nash, Jason Eells, V. Taieb, Iain B. McInnes, Philip J. Mease, Richard Bruce Warren, Nikos Lyris, Jean‐Marie Grouin
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Rheumatology and TherapyVol. 11(5)
Institutions
Griffith University (AU), University of Washington (US), Manchester Academic Health Science Centre (GB), Swedish Medical Center (US), Swedish Medical Center (US), UCB Pharma (France) (FR), UCB Pharma (United Kingdom) (GB), NIHR Manchester Biomedical Research Centre (GB), Université de Rouen Normandie (FR), University of Glasgow (GB)